Erasca, Inc. (ERAS)
| Market Cap | 2.21B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -96.02M |
| Shares Out | 116.14M |
| EPS (ttm) | -0.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 64,785 |
| Open | 19.14 |
| Previous Close | 19.26 |
| Day's Range | 18.50 - 19.79 |
| 52-Week Range | 14.51 - 24.47 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 30.20 (+58.4%) |
| Est. Earnings Date | Oct 28, 2021 |
About ERAS
Erasca is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Molecular alterations in RAS and the MAPK pathway account for approximately 5.5 million new cases of cancer worldwide per year. We have assembled what we believe to be the deepest, wholly-owned or controlled RAS/MAPK pathway-focused pipeline in the industry, comprising 11 modality-agnostic programs aligned with our three therapeutic strategies of: (1) targeting key ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for Erasca stock is "Buy." The 12-month stock price forecast is 30.20, which is an increase of 58.45% from the latest price.
News
Erasca is Named One of Fierce Biotech's “Fierce 15” Biotechnology Companies of 2021
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pa...
Erasca (ERAS) Inks Deal With Pfizer for Colorectal Cancer Study
Erasca (ERAS) signs an agreement with Pfizer for a clinical study, which will evaluate ERAS-007 in combination with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer.
Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protocol Evaluating ERAS-007 in Mult...
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is believed to have broad therapeutic applicability across a wide range of tumor types and indications ERAS-007, a potential best-in-class ERK1/2 in...
Erasca Reports Second Quarter 2021 Financial Results and Business Updates
Successfully closed $345 million upsized IPO in July 2021
Erasca Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ...
SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pat...
Erasca Announces Pricing of Upsized Initial Public Offering
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pat...
Erasca IPO Registration Document (S-1)
Erasca, Inc. has filed to go public with an IPO on the NASDAQ.